RESUMO
Objective To explore the clinical characteristics,diagnosis,therapy and prognostic features of granulocytic sarcoma (GS).Methods Retrospective analysis was used to analyse 10 cases who were diagnosed with GS.Results Five patients were diagnosed with primary GS.GS was accompanied by APL in one case,CML in 3 cases and MDS in one case.Patients were treated with resection and chemotherapy,or imatinib treatment.Follow-up data were available from 9 patients,with 2 patients being still alive.The survival of one patient who received high-dose cytarabine chemotherapy was 66 months.The other 7patients died of tumor-related diseases,and their survival ranged from 4 to 17 months.Conclusion GS is a rarely diagnosed disease.A correct diagnosis of GS depends on detailed morphological examination and immunohistochemical study.The clinical outcome of patients is poor,and AML-type chemotherapy is the proper treatment for GS.High-intensity chemotherapy and hematopoietic stem cell transplantation might improve long-term survival.
RESUMO
Objective To analyze the correlation between the expression of HIF-1α in multiple myeloma (MM) and clinical indexes in order to illustrate the expression and implication of HIF-1α gene in MM. Methods RQ-PCR method was used to amplify HIF-1α mRNA of bone marrow mononuclear cells isolated from 28 cases of MM patients and the control group. β-actin was used as internal standard. HIF-1α mRNA expression was analyzed by SDS software and the ratios of HIF-1α/ β-actin were calculated. Results The relative expression level of HIF-1α mRNA in MM bone marrow mononuclear cells was 12.68 times as that in control group. HIF-1α mRNA was positively correlated with β2-MG (r =0.575, P =0.000), ESR (r =0.522,P =0.000), LDH (r=0.286, P=0.044) and CRP (r =0.356, P =0.011). There was a negative correlation between HIF-1α mRNA and Hb (r =-0.556, P =0.000). Conclusion The expression of HIF-1α mRNA was up-regulated and HIF-1α was related to a number of clinical indexes. HIF-1α may be used to estimate the progress of MM and hopeful to be a new molecular target in cancer therapy.